Neurodevelopmental disorder

6 trials 3 recruiting MedDRA PT
6 Registered trials
3 Recruiting
6 Unique sponsors
6 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 4
N Neurology/Psychiatry (ATC N) 1
A Gastroenterology (ATC A) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 6 substances
Phase III: 2 Phase II: 2 Phase I: 1 Phase I (First in Human): 1

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase III

2 trials
  • Grin Therapeutics Inc. Commercial
    RADIPRODIL
    2023-509672-42-00 8 countries 2023 n=56 Orphan
    Recruiting
  • Intrabio Limited Commercial
    L-ACETYLLEUCINE
    2025-523828-51-00 3 countries n=20 Orphan
    Pending

Phase II

2 trials
  • Centre Hospitalier Universitaire De Nantes Academic
    CARBIDOPA; LEVODOPA
    2024-514852-34-01 1 country 2026 n=7
    Recruiting
  • University Of Cologne Academic
    ZINC ACETATE DIHYDRATE
    2024-512735-72-00 1 country 2024 n=12
    Ended

Phase I

1 trial
  • Iama Therapeutics S.r.l. Commercial
    IMP not specified
    2023-507454-33-00 1 country 2024 n=72
    Ended

Phase I (First in Human)

1 trial
  • Fundacija CTNNB1 Ustanova Za Raziskave Na Podrocju Genske Terapije Academic
    ADENO-ASSOCIATED VIRAL VECTOR SEROTYPE 9 CONTAINING THE HUMAN CTNNB1 GENE
    2025-522719-40-00 1 country 2025 n=12 Orphan
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Iama Therapeutics S.r.l. Commercial 1 Phase I 0
Grin Therapeutics Inc. Commercial 1 Phase III 1
Intrabio Limited Commercial 1 Phase III 0
Centre Hospitalier Universitaire De Nantes Academic 1 Phase II 1
University Of Cologne Academic 1 Phase II 0
Fundacija CTNNB1 Ustanova Za Raziskave Na Podrocju Genske Terapije Academic 1 Phase I (First in Human) 1
New trials by year
2023
1
2024
2
2025
1
2026
1
← All indication landscapes